TEPP-46, a small-molecule PKM2 activator, can protect against DKD by inhibiting the production of toxic glucose metabolites and increasing PGC-1α to restore mitochondrial function (Qi et al., 2017). Here, PPARGC1A is linked to diabetic kidney disease.